Similarly, IGFBP7 hyper‐methylated glioma had higher clinical overall survival compared with IGFBP7 hypo‐methylated glioma in TCGA‐GBMLGG and CGGA‐GBMLGG datasets (Figure 7F). This evidence concerns the gene IGFBP7 and central nervous system cancer.